About one-quarter of patients with MCI progress to dementia

About one-quarter of patients with MCI progress to dementia

(HealthDay)—About 22 percent of patients with mild cognitive impairment (MCI) progress to dementia within three years, and depression symptoms modify the prognosis, according to a study published in the March/April issue of the Annals of Family Medicine.

Hanna Kaduszkiewicz, M.D., from the Center for Psychosocial Medicine in Hamburg, Germany, and colleagues recruited 357 patients with MCI aged 75 years or older and followed them for three years. The patients were retrospectively categorized according to the course of impairment over time into remittent, fluctuating, stable, and progressive courses of MCI.

The researchers found that 41.5 percent of patients had symptom remission with normal cognitive function at 1.5 and three years; 21.3, 14.8, and 22.4 percent had a fluctuating course, stable symptoms, and progression to dementia. The risk of advancing from one course to the next was increased for patients with symptoms of depression, impairment in more than one cognitive domain, or more , and for older patients. The best indicator for differentiating between remittent and progressive MCI was the result on a test of the ability to learn and reproduce new material 10 minutes later. The prognosis was modified by depression.

"In primary care, about one-quarter of patients with MCI have progression to dementia within the next three years," the authors write "When transferring the concept of MCI into clinical diagnostic algorithms (e.g., Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition), however, we should not forget that three-quarters of with MCI stayed cognitively stable or even improved within three years. They should not be alarmed unnecessarily by receiving such a diagnosis."

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Putting dementia carers in control

Sep 18, 2014

Experts will explore how improved support and powers for people caring for loved-ones with dementia can improve quality of life for both patients and carers around the UK.

Lilly, AstraZeneca team up on Alzheimer's drug

Sep 16, 2014

Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing.

User comments